Literature DB >> 6603896

Sequential methotrexate-5-fluorouracil treatment of squamous cell carcinoma of the head and neck.

U Ringborg, G Ewert, J Kinnman, P G Lundqvist, H Strander.   

Abstract

Thirty-six patients with squamous cell carcinoma of the head and neck were treated with sequential methotrexate-5-fluorouracil followed by leucovorin rescue. The frequency of objective tumor regression obtained was 64% (complete response + partial response) with 19% complete regression. In 20 not previously treated patients, the objective response rate was 70%. Approximately the same result was obtained for tumors of different anatomical sites of the head and neck. The degree of differentiation of the squamous cell carcinoma did not seem to be of prognostic importance for the initial tumor response. Toxicity was very mild and usually disappeared when the interval between the chemotherapy courses was prolonged from 1 to 2 weeks. Radiotherapy could be added sequentially to the treatment without measurable escalated toxicity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6603896     DOI: 10.1002/1097-0142(19830915)52:6<971::aid-cncr2820520606>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma.

Authors:  Vandana Singh Kushwaha; Seema Gupta; Nuzhat Husain; Huma Khan; M P S Negi; Naseem Jamal; Ashim Ghatak
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

2.  Sequential methotrexate (MTX) and 5-fluorouracil (FU) in human tumor xenografts.

Authors:  K Wayss; R Herrmann; J Mattern; M Volm
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

Review 3.  Clinical trials with fluorinated pyrimidines in patients with head and neck cancer.

Authors:  M al-Sarraf
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.